Lymelab Pharma Sp. z o.o. sp. k. (Poland)

Main Activities: Research and Development in Biotechnology (except Nanobiotechnology)

Secondary Activities: All Other Miscellaneous Crop Farming | Pharmaceutical Preparation Manufacturing | Department Stores | Other Direct Selling Establishments | Scientific Research and Development Services | All Other Miscellaneous Schools and Instruction | All Other Miscellaneous Ambulatory Health Care Services

Full name: Lymelab Pharma Sp. z o.o. sp. k.

Profile Updated: July 25, 2025

Lymelab Pharma Sp. z o.o. sp. k. is an enterprise located in Poland, with the main office in Warsaw. The enterprise operates in the Research and Development in Biotechnology (except Nanobiotechnology) industry. Lymelab Pharma Sp. z o.o. sp. k. was incorporated on November 25, 2020. The latest financial highlights indicate a net sales revenue increase of 731.24% in 2024. Its’ total assets recorded a growth of 162.92%. The net profit margin of Lymelab Pharma Sp. z o.o. sp. k. increased by 886.95% in 2024.

Headquarters
Ul. Jana Kochanowskiego 49A
Warsaw; Mazowieckie; Postal Code: 01-864

Contact Details: Purchase the Lymelab Pharma Sp. z o.o. sp. k. report to view the information.

Basic Information

Financial Auditors:

Purchase the Lymelab Pharma Sp. z o.o. sp. k. report to view the information.

Incorporation Date:

November 25, 2020

Key Executives

Purchase this report to view the information.

Associate

Purchase this report to view the information.

Associate Partner

Purchase this report to view the information.

Limited Partner

Purchase this report to view the information.

Limited Partner

Company Performance

Financial values in the chart are available after Lymelab Pharma Sp. z o.o. sp. k. report is purchased.

Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service

Key Financial Highlights

Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.

Net sales revenue

731.24%▲

Total operating revenue

565.74%▲

Operating profit (EBIT)

-142.97%▼

EBITDA

-109.61%▼

Net Profit (Loss) for the Period

-124.2%▼

Total Assets

162.92%▲

Total Equity

-116.03%▼

Operating Profit Margin (ROS)

718.36%▲

Net Profit Margin

886.95%▲

Return on Equity (ROE)

1.96%▲

Debt/Equity

57.91%▲

Quick Ratio

-0.56%▼

Similar companies